We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
Read MoreHide Full Article
AVEO Pharmaceuticals, Inc. reported earnings of 10 cents per share in the third quarter of 2019, surpassing the Zacks Consensus Estimate of 1 cent. It also rebounded from the year-ago loss of 18 cents.
The company’s top line comprises collaboration and licensing revenues plus partnership royalties. Total revenues in the reported quarter were $25.7 million, up from $2.5 million in the year-ago period. Revenues also comprehensively beat the Zacks Consensus Estimate of $13 million.
Shares of AVEO were up 8.8% following the company’s earnings release on Nov 12. However, the stock has plunged 65% so far this year against the industry’s increase of 1.2%.
In August 2017, AVEO and partner EUSA Pharma received an approval from the European Commission of its VEGF tyrosine kinase inhibitor Fotivda (tivozanib) for the first-line treatment of advanced renal cell carcinoma (RCC). It is the first approved drug in the company’s portfolio. AVEO is focused on launching the medicine across Europe and other countries.
Operating Expenses
Research & development expenses were down 23.1% year over year to $4 million. However, general and administrative expenses increased 7.4% year over year to $2.9 million.
Cash Guidance
AVEO had around $57.7 million worth of cash, cash equivalents and marketable securities as of Sep 30, 2019 compared with $40.2 million on June 30, 2019. The company believes that this will help fund its planned operations through the second quarter of 2021.
Other Updates
In September 2019, AVEO announced updated data from the second prespecified analysis of overall survival (OS) in a late-stage TIVO-3 study on Fotivda. This randomized, open-label phase III study evaluated Fotivda for the treatment of patients with highly refractory metastatic renal cell carcinoma (RCC) compared with Bayer AG’s (BAYRY - Free Report) Nexavar (sorafenib).
These results include an OS hazard ratio of less than one that favors Fotivda.
Earlier this month, AVEO provided a regulatory update after a meeting with the FDA authorities to discuss OS results from the phase III TIVO-3 study to proceed with a New Drug Application (NDA) for Fotivda. The company plans to file an NDA for Fotivda in the first quarter of 2020 and expects to report results from the final OS analysis in June 2020.
However, during the review, if the final analysis yields an OS hazard ratio of more than 1, AVEO will withdraw its NDA for Fotivda.
Meanwhile, in September 2019, AVEO initiated enrollment in the Ib/II DEDUCTIVE study evaluating Fotivda in combination with AstraZeneca’s (AZN - Free Report) PD-L1 inhibitor Imfinzi (durvalumab) for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma, who have not received prior systemic therapy.
AVEO is also evaluating Fotivda in combination with Bristol-Myers’ (BMY - Free Report) PD-1 inhibitor, Opdivo (nivolumab) in the Ib/II TiNivo study for the treatment of advanced or metastatic RCC.
Apart from Fotivda, AVEO has a promising candidate, ficlatuzumab, in its pipeline. It is currently being evaluated in early-mid/stage studies for various oncological indications. Last week, AVEO along with partner Biodesix, Inc initiated the phase II CyFi-2 study, which evaluated ficlatuzumab in combination with high-dose cytarabine versus high-dose cytarabine alone in patients with relapsed/refractory acute myeloid leukemia (AML).
AVEO Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
AVEO Pharmaceuticals, Inc. reported earnings of 10 cents per share in the third quarter of 2019, surpassing the Zacks Consensus Estimate of 1 cent. It also rebounded from the year-ago loss of 18 cents.
The company’s top line comprises collaboration and licensing revenues plus partnership royalties. Total revenues in the reported quarter were $25.7 million, up from $2.5 million in the year-ago period. Revenues also comprehensively beat the Zacks Consensus Estimate of $13 million.
Shares of AVEO were up 8.8% following the company’s earnings release on Nov 12. However, the stock has plunged 65% so far this year against the industry’s increase of 1.2%.
In August 2017, AVEO and partner EUSA Pharma received an approval from the European Commission of its VEGF tyrosine kinase inhibitor Fotivda (tivozanib) for the first-line treatment of advanced renal cell carcinoma (RCC). It is the first approved drug in the company’s portfolio. AVEO is focused on launching the medicine across Europe and other countries.
Operating Expenses
Research & development expenses were down 23.1% year over year to $4 million. However, general and administrative expenses increased 7.4% year over year to $2.9 million.
Cash Guidance
AVEO had around $57.7 million worth of cash, cash equivalents and marketable securities as of Sep 30, 2019 compared with $40.2 million on June 30, 2019. The company believes that this will help fund its planned operations through the second quarter of 2021.
Other Updates
In September 2019, AVEO announced updated data from the second prespecified analysis of overall survival (OS) in a late-stage TIVO-3 study on Fotivda. This randomized, open-label phase III study evaluated Fotivda for the treatment of patients with highly refractory metastatic renal cell carcinoma (RCC) compared with Bayer AG’s (BAYRY - Free Report) Nexavar (sorafenib).
These results include an OS hazard ratio of less than one that favors Fotivda.
Earlier this month, AVEO provided a regulatory update after a meeting with the FDA authorities to discuss OS results from the phase III TIVO-3 study to proceed with a New Drug Application (NDA) for Fotivda. The company plans to file an NDA for Fotivda in the first quarter of 2020 and expects to report results from the final OS analysis in June 2020.
However, during the review, if the final analysis yields an OS hazard ratio of more than 1, AVEO will withdraw its NDA for Fotivda.
Meanwhile, in September 2019, AVEO initiated enrollment in the Ib/II DEDUCTIVE study evaluating Fotivda in combination with AstraZeneca’s (AZN - Free Report) PD-L1 inhibitor Imfinzi (durvalumab) for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma, who have not received prior systemic therapy.
AVEO is also evaluating Fotivda in combination with Bristol-Myers’ (BMY - Free Report) PD-1 inhibitor, Opdivo (nivolumab) in the Ib/II TiNivo study for the treatment of advanced or metastatic RCC.
Apart from Fotivda, AVEO has a promising candidate, ficlatuzumab, in its pipeline. It is currently being evaluated in early-mid/stage studies for various oncological indications. Last week, AVEO along with partner Biodesix, Inc initiated the phase II CyFi-2 study, which evaluated ficlatuzumab in combination with high-dose cytarabine versus high-dose cytarabine alone in patients with relapsed/refractory acute myeloid leukemia (AML).
AVEO Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
AVEO Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | AVEO Pharmaceuticals, Inc. Quote
Zacks Rank
AVEO currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>